Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma C Morris

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2017
<i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer PatientsYuan Chen, Shao-An Xue, Shahriar Behboudi, et al.
Blood|May 25, 2011
Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigenSharyn Thomas, Shao-An Xue, Charles R M Bangham, et al.
Blood|June 18, 2002
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimenKarl S Peggs, Emma C Morris, Panos D Kottaridis, et al.
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
British Journal of Haematology|August 20, 2015
Guidelines on the management and admission to intensive care of critically ill adult patients with haematological malignancy in the UKMatt P Wise, Rosemary A Barnes, Simon V Baudouin, et al.
Haematologica|January 24, 2016
Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapyAngelika Holler, Mathias Zech, Sara Ghorashian, et al.
Blood|October 25, 2003
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesKarl S Peggs, Kirsty Thomson, Daniel P Hart, et al.
British Journal of Haematology|March 5, 2003
Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemiaEmma C Morris, Georgina Harrison, Clifford C Bailey, et al.
The Journal of Allergy and Clinical Immunology. Global|January 8, 2024
Allogeneic hematopoietic stem cell transplantation outcome in oldest known surviving patients with Wiskott-Aldrich syndromeAriharan Anantharachagan, Sook Yin Loh, Siobhan O Burns, et al.
British Journal of Haematology|January 16, 2014
Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responsesBenjamin Uttenthal, Irma Martinez-Davila, Adam Ivey, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2017
<i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer PatientsYuan Chen, Shao-An Xue, Shahriar Behboudi, et al.
Blood|May 25, 2011
Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigenSharyn Thomas, Shao-An Xue, Charles R M Bangham, et al.
Blood|June 18, 2002
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimenKarl S Peggs, Emma C Morris, Panos D Kottaridis, et al.
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
British Journal of Haematology|August 20, 2015
Guidelines on the management and admission to intensive care of critically ill adult patients with haematological malignancy in the UKMatt P Wise, Rosemary A Barnes, Simon V Baudouin, et al.
Haematologica|January 24, 2016
Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapyAngelika Holler, Mathias Zech, Sara Ghorashian, et al.
Blood|October 25, 2003
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responsesKarl S Peggs, Kirsty Thomson, Daniel P Hart, et al.
British Journal of Haematology|March 5, 2003
Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemiaEmma C Morris, Georgina Harrison, Clifford C Bailey, et al.
The Journal of Allergy and Clinical Immunology. Global|January 8, 2024
Allogeneic hematopoietic stem cell transplantation outcome in oldest known surviving patients with Wiskott-Aldrich syndromeAriharan Anantharachagan, Sook Yin Loh, Siobhan O Burns, et al.
British Journal of Haematology|January 16, 2014
Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responsesBenjamin Uttenthal, Irma Martinez-Davila, Adam Ivey, et al.
Pageof 8